CINECA IRIS Institutional Research Information System

MINUTOLO, FILIPPO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.415
EU - Europa 9.443
AS - Asia 9.170
SA - Sud America 1.357
AF - Africa 359
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 6
Totale 39.784
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.758
IT - Italia 4.311
SG - Singapore 2.822
CN - Cina 2.730
HK - Hong Kong 1.559
BR - Brasile 1.171
SE - Svezia 1.150
DE - Germania 970
BG - Bulgaria 726
TR - Turchia 580
CA - Canada 545
GB - Regno Unito 452
VN - Vietnam 446
RU - Federazione Russa 329
UA - Ucraina 314
IN - India 306
FI - Finlandia 304
FR - Francia 285
KR - Corea 192
CH - Svizzera 138
JP - Giappone 114
AT - Austria 107
BE - Belgio 75
CI - Costa d'Avorio 71
NG - Nigeria 71
BD - Bangladesh 66
NL - Olanda 59
AR - Argentina 58
PL - Polonia 54
MX - Messico 50
ZA - Sudafrica 47
ES - Italia 45
IQ - Iraq 39
ID - Indonesia 35
MA - Marocco 34
SA - Arabia Saudita 32
SN - Senegal 31
EC - Ecuador 30
PK - Pakistan 28
UZ - Uzbekistan 27
VE - Venezuela 27
AU - Australia 26
CO - Colombia 25
IR - Iran 25
EG - Egitto 21
CZ - Repubblica Ceca 16
JO - Giordania 16
KE - Kenya 16
GR - Grecia 15
AZ - Azerbaigian 14
IE - Irlanda 14
IL - Israele 14
TN - Tunisia 14
RO - Romania 13
TW - Taiwan 13
CL - Cile 12
DK - Danimarca 12
DO - Repubblica Dominicana 11
GH - Ghana 11
LT - Lituania 11
MO - Macao, regione amministrativa speciale della Cina 11
PY - Paraguay 11
TT - Trinidad e Tobago 11
UY - Uruguay 11
NP - Nepal 10
AE - Emirati Arabi Uniti 9
BJ - Benin 9
KZ - Kazakistan 9
MY - Malesia 9
OM - Oman 9
DZ - Algeria 8
NZ - Nuova Zelanda 8
BY - Bielorussia 7
JM - Giamaica 7
PE - Perù 7
CR - Costa Rica 6
HU - Ungheria 6
LK - Sri Lanka 6
PA - Panama 6
TH - Thailandia 6
AL - Albania 5
BA - Bosnia-Erzegovina 5
BB - Barbados 5
ET - Etiopia 5
PS - Palestinian Territory 5
RS - Serbia 5
AM - Armenia 4
AO - Angola 4
HN - Honduras 4
PT - Portogallo 4
QA - Qatar 4
SY - Repubblica araba siriana 4
BN - Brunei Darussalam 3
BO - Bolivia 3
EU - Europa 3
GA - Gabon 3
GE - Georgia 3
KW - Kuwait 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
Totale 39.731
Salva come PNG Salva come JPEG
Città #
Woodbridge 2.089
Ashburn 2.012
Singapore 1.560
Hong Kong 1.546
Ann Arbor 1.419
Fairfield 1.362
Chandler 1.349
Houston 1.242
Serra 1.211
Dallas 933
Milan 905
Santa Clara 873
Sofia 726
Shanghai 631
Beijing 586
Seattle 550
Wilmington 505
Cambridge 482
New York 460
Ottawa 457
Jacksonville 397
Izmir 391
Boardman 347
Princeton 322
Lawrence 275
Los Angeles 267
Nanjing 261
Medford 256
Hefei 246
Rome 170
Seoul 166
Des Moines 147
Dearborn 146
Pisa 146
Dong Ket 136
Florence 134
Istanbul 134
Bern 122
Redondo Beach 121
Redwood City 119
London 113
Marseille 111
Nanchang 111
Boulder 110
Munich 105
Buffalo 98
Vienna 87
São Paulo 84
San Diego 79
Council Bluffs 77
Tokyo 72
Abidjan 69
Lagos 69
The Dalles 65
Jüchen 60
Ho Chi Minh City 59
Columbus 58
Ogden 56
Livorno 53
Shenyang 49
Brussels 48
Hyderabad 48
Frankfurt am Main 46
Hebei 46
Kunming 45
Lucca 45
Pune 42
Turku 40
Guangzhou 39
Washington 39
Chicago 38
Tianjin 38
Belo Horizonte 37
Hanoi 37
Mumbai 37
Nürnberg 37
San Francisco 37
Norwalk 35
Rio de Janeiro 35
Warsaw 35
Jiaxing 33
Dakar 31
Hangzhou 31
Auburn Hills 28
Changsha 28
Nuremberg 28
Bologna 27
Jinan 25
Phoenix 24
Toronto 24
Fuzhou 23
San Jose 23
Düsseldorf 22
Brasília 21
Casablanca 21
Helsinki 21
Louvain-la-Neuve 21
Palermo 20
Tashkent 20
Vicopisano 20
Totale 28.081
Salva come PNG Salva come JPEG
Nome #
COMPOSTO INIBITORE DELL’ENZIMA LATTATO DEIDROGENASI (LDH) E COMPOSIZIONE FARMACEUTICA CHE COMPRENDE TALE COMPOSTO 346
4-Aryliden-2-methyloxazol-5(4H)-one as a new scaffold for selective reversible MAGL inhibitors 315
Glycoconjugated metal complexes as cancer diagnostic and therapeutic agents 281
Receptor-based virtual screening evaluation for the identification of estrogen receptor β ligands 252
Phenylpropanoids and flavonoids from Phlomis kurdica as inhibitors of human lactate dehydrogenase. 252
GLUT1 and LOX inhibitors as perspective anticancer agents tackling glucose avidity and ECM remodeling in tumors 245
Synthesis and biological evaluation of non-glucose glycoconjugated N-hydroyxindole class LDH inhibitors as anticancer agents 227
New activators of SIRT1 enzyme for the treatment of cardiovascular and cardiometabolic pathologies 226
Identification of Lactate Dehydrogenase 5 Inhibitors using Pharmacophore- Driven Consensus Docking 225
Sonde diagnostiche per evidenziare all’infrarosso cellule e tessuti affetti da condizioni patologiche o metaboliche 213
New NO-Releasing Pharmacodynamic Hybrids of Losartan and Its Active Metabolite: Design,Synthesis, and Biopharmacological Properties 209
Synthesis and Biological Evaluation of New Glycoconjugated LDH Inhibitors as Anticancer Agents 205
A Virtual Screening Study for Lactate Dehydrogenase 5 Inhibitors by using a Pharmacophore-Based Approach 204
Development of terphenyl-2-methyloxazol-5(4H)-one derivatives as selective reversible MAGL inhibitors 204
Nuovi attivatori dell’enzima SIRT1 per il trattamento delle patologie cardiovascolari e cardiometaboliche 204
First examples of H2S-releasing glycoconjugates: stereoselective synthesis and anticancer activities 201
Synthesis of Anthranylaldoxime Derivatives as Estrogen Receptor Ligands and Computational Prediction of Binding Modes 195
Lactate dehydrogenase-A inhibition induces human glioblastoma multiforme stem cell differentiation and death 195
A Convenient Three-Component Synthesis of Substituted Cyclopentadienyl Tricarbonyl Rhenium Complexes 193
Salicylaldoxime derivatives as new leads for the development of carbonic anhydrase inhibitors 192
Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials 192
Rational Development of MAGL Inhibitors 192
Salicylaldoximes and anthranylaldoximes as alternatives to phenol-based estrogen receptor ligands 190
Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor 190
Salicylaldoximes and anthranylaldoximes as alternatives to phenol-based estrogen receptor ligands 188
Discovery of N-Hydroxyindole-Based Inhibitors of Human Lactate Dehydrogenase Isoform a (LDH-A) as Starvation Agents against Cancer Cells 187
Glucose transporters: production, crystallization and inhibition 187
A Polymer-Supported Phosphazine as a Stable and Practical Reagent in the Three-Component Synthesis of Substituted (Cyclopentadienyl)tricarbonylrhenium Complexes 184
CB2-Selective Cannabinoid Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides 184
Structural optimization of 4-chlorobenzoylpiperidine derivatives for the development of potent, reversible and selective monoacylglycerol lipase (MAGL) inhibitors 184
Synthesis and dopaminergic properties of the two enantiomers of 3-(3,4-dimethylphenyl)-1-propylpiperidine, a potent and selective dopamine D4 receptor ligand 183
METAL SALT-PROMOTED ALDOL REACTION OF SILYL ENOL ETHERS WITH ALDEHYDES 183
COMPOUNDS INHIBITING THE ENZYME LACTATE DEHYDROGENASE (LDH), PHARMACEUTICAL COMPOSITIONS AND USES THEREOF 183
Characterization of the Saffron Derivative Crocetin as an Inhibitor of Human Lactate Dehydrogenase 5 in the Antiglycolytic Approach against Cancer 183
4-[6-(dansylamino)hexylamino]-7-methyl-2-phenyl-1,8-naphthyridine as a new potential fluorescent probe for studying A1-adenosine receptor 182
Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer 182
Historical perspective of tumor glycolysis: a century with Otto Warburg 181
Phosphonomethylphosphorylmethyl(oxy)-analogues of geranylgeranyl diphosphate as stable and selective geranylgeranyl protein transferase inhibitors 181
Antiproliferative oxime derivatives that inhibit glucose transporter 1 (GLUT1) in cancer cells 181
Identification of new FYN kinase inhibitors using a FLAP-based approach 181
Systems Structural Biology Analysis of Ligand Effects on ERα Predicts Cellular Response to Environmental Estrogens and Anti-hormone Therapies 181
Tackling tumors by exploiting their glucose avidity and high rate of glycolysis 181
Diagnostic probes to detect cells and tissues afflicted with a pathological or metabolic condition by means of infrared spectroscopy 181
Discovery of long-chain salicylketoxime derivatives as monoacylglycerol lipase (MAGL) inhibitors 179
Estrogen receptor ligands: a patent review update 178
Sulfonamido-derivatives of unsubstituted carbazoles as BACE1 inhibitors 178
Design, Synthesis, and Evaluation of GLUT Inhibitors 178
Hypoxia-activated lysyl oxidase (LOX) inhibitors in the treatment of highly invasive and metastatic cancer 177
Synthesis of stable analogues of geranylgeranyl diphosphate possessing a (Z,E,E)-geranylgeranyl side chain, docking analysis, and biological assays for prenyl protein transferase inhibition 177
Reactive Oxygen Species Synergize to Potently and Selectively Induce Cancer Cell Death 177
Spirocyclic Benzopyran-based derivatives as new anti-ischemic activators of mitochondrial ATP-sensitive potassium channel 177
Anticancer Agents That Counteract Tumor Glycolysis 176
Dual Targeting of the Warburg Effect with a Glucose-Conjugated Lactate Dehydrogenase Inhibitor 174
Highly Selective Salicylketoxime-Based Estrogen Receptor β Agonists Display Antiproliferative Activities in a Glioma Model 174
Boronic Acids in the Three-Component Synthesis of Carbon-Substituted Cyclopentadienyl Tricarbonyl Rhenium Complexes 173
7-Nitrobenzofurazan (NBD)-Derivatives Of 5'-N-Ethylcarboxamidoadenosine (NECA) As New Fluorescent Probes For Human A3 Adenosine Receptors 173
An update on therapeutic opportunities offered by cancer glycolytic metabolism 173
Cyclic Ketoximes as Estrogen Receptorβ Selective Agonists 173
Risks and Benefits Related to Alimentary Exposure to Xenoestrogens 173
Pharmacological study on the cardiovascular activity of no-sartans, pharmacodynamic hybridsexhibiting at1-antagonist and no-donor properties 172
Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia 171
Selective and potent agonists for estrogen receptor beta derived from molecular refinements of salicylaldoximes 170
Discovery of 1,5-Diphenylpyrazole-3-Carboxamide Derivatives as Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors 170
Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways 170
Computationally driven discovery of phenyl(piperazin-1-yl)methanone derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors 170
Design, synthesis, ADME and biological evaluation of benzylpiperidine and benzylpiperazine derivatives as novel reversible monoacylglycerol lipase (MAGL) inhibitors 168
Selective activators of estrogen receptor beta based on the aldoxime and ketoxime scaffolds 167
Anticancer agents interacting with membrane glucose transporters 167
New Benzopyran-Based Openers of the Mitochondrial ATP-Sensitive Potassium Channel with Potent Anti-Ischemic Properties 165
Diaryl-substituted salicyl- and anthranyl-ketoximes as potential estrogen receptor ligands 165
NO-Sartans: A New Class of Pharmacodynamic Hybrids as Cardiovascular Drugs 165
Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds 165
Functionalized aliphatic polyketones with germicide activity 165
Drug-likeness of multiple-binding drugs 164
New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2) 164
Synthesis of sulfonamide-containing N-hydroxyindole-2-carboxylates as inhibitors of human lactate dehydrogenase-isoform 5 164
a) Analgesici "pesanti": i Dramadoli; b) Ombrelli molecolari 163
Biphenyl-Derivatives Possessing Tertiary Amino Groups as ß-Secretase (BACE1) Inhibitors 163
Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells 163
Curaxins: A New Family of Non-genotoxic Multitargeted Anticancer Agents 162
N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation 162
Radiosensitizing potentialof small organic molecules toward hypoxic tumor cells in the radiotherapy 160
Preclinical emergence of novel lactate dehydrogenase inhibitors as potent antitumor agents in hypoxic models of pancreatic cancer: molecular mechanisms underlying their synergistic interaction with gemcitabine 160
Synthesis of a Resveratrol Analogue with High Ceramide-Mediated Proapoptotic Activity on Human Breast Cancer Cells 160
Variously substituted (phosphonoacetamido)oxy analogues of geranylgeranyl diphosphate (GGdP) as GGdP-transferase (GGTase) inhibitors and antiproliferative agents 159
Binding investigation and preliminary optimisation of the 3-amino-1,2,4-triazin-5(2H)-one core for the development of new Fyn inhibitors 158
Triazole-substituted N-hydroxyindol-2-carboxylates as inhibitors of isoform 5 of human lactate dehydrogenase (hLDH5) 157
N-Hydoxyindoles: novel, selective, and efficient inhibitors of isoform 5 of human lactate dehydrogenase (hLDH-5) 156
Synthesis of aniline-type analogues of farnesyl diphosphate and their biological assays for prenyl protein transferase inhibitory activity 156
Natural compounds as inhibitors of lactate dehydrogenase 155
An Update on Patents Covering Agents That Interfere with the Cancer Glycolytic Cascade 155
A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1 155
Salicylketoximes that target glucose transporter 1 restrict energy supply to lung cancer cells 155
Ceramide analogues in apoptosis: a new strategy for anticancer drug development 154
New N-n-propyl-substituted 3-Aryl and 3-Cyclohexyl piperidines as partial agonists at the D4 dopamine receptor 154
Small-molecule inhibitors of human LDH5 153
a) Dendrimeri a rilascio controllato di ossido d'azoto; b) Platensimicina: un nuovo antibiotico per un nuovo target 152
QSAR models for predicting enzymatic hydrolysis of new chemical entities in 'soft-drug' design 152
Liposomal delivery of a Pin1 inhibitor complexed with cyclodextrins as new therapy for high-grade serous ovarian cancer 152
Reversible Monoacylglycerol Lipase Inhibitors: Discovery of a New Class of Benzylpiperidine Derivatives 149
Totale 18.242
Salva come PNG Salva come JPEG
Categoria #
all - tutte 107.397
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 107.397
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.476 0 0 0 0 0 157 163 236 260 143 151 366
2021/20223.401 116 293 80 199 521 490 129 194 84 120 180 995
2022/20233.837 489 497 260 395 467 506 41 296 606 29 205 46
2023/20243.378 446 423 353 261 486 585 126 102 57 74 121 344
2024/20258.764 84 391 254 525 671 784 644 498 927 1.167 932 1.887
2025/20265.289 527 1.164 1.130 741 846 881 0 0 0 0 0 0
Totale 40.348